Arthritic Therapeutic: Transforming the Healing Process with Personalized Medications

Highlights

• Introduction
• Role of biomarkers in personalized treatment plan
• Evolving landscape of the Asia-Pacific arthritic therapeutic industry
• Recent developments in the industry

The term ‘arthritic therapeutic’ refers to a range of medical treatments designed to manage and treat various forms of arthritis, including rheumatoid arthritis and osteoarthritis. These conditions affect individuals' quality of life and require effective treatment options. Hence, the landscape of arthritic therapeutic is continually expanding to address the healthcare needs of the growing population affected by this chronic condition. These treatments, including NSAIDs, biologics, and advanced therapies, aim to enhance the quality of life for individuals with arthritis by reducing pain, lowering inflammation, and improving joint function. 

Moreover, the global emphasis on enhancing healthcare infrastructure drives the growth of the arthritic therapeutic industry. Enhanced healthcare infrastructure facilitates easier diagnosis, treatment, and management of arthritis-related issues. This initiative includes the establishment of specialized clinics, diagnostic facilities, and increased availability of arthritis therapies. Improved infrastructure enables early and accurate disease detection and streamlines the delivery of personalized treatments, thereby optimizing industry expansion. 

Biomarkers for precision medicine in arthritic treatment

The increasing emphasis on personalized medicine represents a substantial opportunity for the arthritic therapeutic market. This approach customizes treatments for each patient by considering their specific genetic profiles, medical histories, and other relevant factors. The goal is to maximize treatment effectiveness while minimizing potential side effects.

Biomarkers are essential in personalized medicine as they offer insights into how a patient responds to treatment. While biomarkers predict treatment outcomes, they don't definitively identify the best treatment option. Instead, they give patients information about the chances of outcomes for available treatments. Understanding a patient's unique biomarker profile enables clinicians to personalize treatment decisions, aiming to maximize effectiveness and minimize risks for that individual. Biomarkers offer insights into the disease mechanisms, helping clinicians select the most suitable Disease-Modifying Anti-Rheumatic Drug (DMARD) for the patient's condition.

Prime Contributors to the expansion of the Asia-Pacific arthritic therapeutic industry

The rapid economic development and expanding ageing population in Asia-Pacific countries are leading to a higher prevalence of arthritis. This trend is accompanied by a growing incidence of conditions affecting tissues or organs that can be treated with osteoarthritis therapeutics, thereby driving the industry’s growth.

Moreover, increasing investments to advance healthcare infrastructure are expected to fuel robust growth in the arthritis therapeutics market across the Asia-Pacific region. Developed countries in Asia-Pacific, such as Japan, New Zealand, and Australia, maintain high adoption rates of biologic drugs. The region is experiencing advancements in cutting-edge biologic therapies, including TNF inhibitors, interleukin inhibitors, and JAK inhibitors. These innovations are addressing the growing demand for more effective and personalized treatments for arthritis. Among the emerging economies of the Asia-Pacific, China is expected to display the fastest growth with a 9.10% CAGR throughout the forecast timeframe. 

Lupin introduced a biosimilar of Etanercept in the Canadian market

Lupin announced the launch of Rymti, its first biosimilar in Canada, in collaboration with Sandoz Canada in May 2024. Rymti is formulated for treating conditions such as chronic severe plaque psoriasis, active and progressive psoriatic arthritis, juvenile idiopathic arthritis, severe axial spondyloarthritis, and moderate to severe active rheumatoid arthritis in both adults and children. It is also effective for moderate to severe plaque psoriasis. Rymti is approved for all the therapeutic indications of its reference product, Enbrel.

It is offered as a solution for injection in a pre-filled pen and a syringe. The prefilled pen is gaining prominence due to its latex-free nature and easy handling. Patients appreciate its ease of self-injection that improves treatment adherence.

Stempeutics and Alkem jointly launched StemOne in October 2023 for the treatment of knee osteoarthritis

Alkem Laboratories announced that it received approval for the launch of StemOne in India from the Drug Controller General of India (DCGI). StemOne is the first allogeneic cell therapy medication approved for commercial use in India for the treatment of knee osteoarthritis.

The product has been developed by Stempeutics, a group company of Manipal Education and Medical Group, for over 12 years. Stempeutics' proprietary technology platform facilitates an efficient manufacturing process, which helps make the product accessible to patients at an affordable cost.

In conclusion, the arthritic therapeutic industry is evolving rapidly with advancements in personalized medicine and innovative treatments like biosimilars and cell therapies. Moreover, enhanced healthcare infrastructure, particularly in the Asia-Pacific region, is expected to meet the rising demand for effective arthritis management and pioneer a future of improved patient outcomes and quality of life.

For detailed insights into the trend analysis in the healthcare sector, contact our experts today!

Related Post